Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

Area of Science:

• Hepatology
• Virology
• Clinical Trials

Background:

• Chronic hepatitis C treatment response is linked to clinical and viral factors.
• The influence of race and ethnicity on interferon treatment outcomes for hepatitis C has not been extensively studied.

Purpose of the Study:

• To investigate the association between race and response to interferon therapy in patients with chronic hepatitis C.
• To compare treatment outcomes across different racial and ethnic groups in a randomized controlled trial.

Main Methods:

• A large randomized, controlled trial comparing consensus interferon and interferon alfa-2b.
• Evaluation of end-of-treatment and sustained virological response rates based on race and ethnicity.
• Analysis of baseline characteristics including age, hepatitis C virus (HCV) RNA levels, cirrhosis, and viral genotype.

Main Results:

• African-American patients exhibited significantly lower rates of end-of-treatment (5%) and sustained virological response (2%) compared to white patients (33% and 12%, respectively).
• Viral load reduction was less pronounced in African-American patients (0.5 log decrease) than in white patients (2.5 log decrease).
• Hispanic and Asian-American patients did not show statistically significant differences in response rates compared to non-Hispanic white patients.

Conclusions:

• Marked racial disparities exist in virological responses to interferon therapy for chronic hepatitis C.
• These racial differences in treatment response require consideration in clinical trial assessments and patient counseling.
• The underlying reasons for these observed racial differences in treatment efficacy remain unexplained.